Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

BOLD vs DERM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BOLD Captures Overall Composite Edge (36.8 SELL vs 40.9 SELL), While DERM Leads 4–2 on Growth & Valuation Pillars

BOLD Overall Winner 6-Pillar Tally: BOLD 2 – 4 DERM Matrix Metrics: BOLD 4 – 6 DERM

As of Nov 20, 2026, Boundless Bio, Inc. (BOLD) captures the overall head-to-head institutional edge over Journey Medical Corporation (DERM) on higher Unified Composite conviction (36.8/100 SELL vs. 40.9/100 SELL) after splitting the core matrix 4–6 (led by Profitability & Quality, Options & Positioning), while DERM wins 4–2 across the 6-pillar growth and valuation breakdown. BOLD trades at $2.32 (N/M Forward P/E, 0.0% operating margin) versus DERM at $3.30 (8.3x Forward P/E, -2.9% operating margin).

  • Composite vs. Pillar Nuance: While DERM currently prints a higher short-term Unified Composite Score (40.9/100 SELL vs. BOLD 36.8/100 SELL), BOLD captures the overall institutional head-to-head verdict (4–6 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -2.9% operating margin) and revenue trajectory (+0.0% vs. +7.6% YoY).
  • Defensive Composite Rating Caution: Although BOLD compares more favorably head-to-head, both BOLD (36.8/100 SELL) and DERM (40.9/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: BOLD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0); meanwhile DERM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BOLD vs DERM
BOLD NASDAQ Head-to-Head Winner
Boundless Bio, Inc. Common Stock
Pharmaceutical Preparations
$2.32
-2.52% 1D
Market Cap $56.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.08β · 28% Vol
Unified Composite Score
36.8 / 100 SELL
Tech 25.0 Fund 50.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.6%), weak momentum, RSI 35
RSI-14: 35.0 · SMA20: $2.43 · SMA50: $2.52
DERM NASDAQ
Journey Medical Corporation Common Stock
Pharmaceutical Preparations
$3.30
-7.04% 1D
Market Cap $100.2M
TTM Revenue $70M
Forward P/E 8.3x
Beta / 30D Vol 2.08β · 77% Vol
Unified Composite Score
40.9 / 100 SELL
Tech 25.0 Fund 47.0 Flow 72.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.7%), weak momentum, RSI 25
RSI-14: 25.0 · SMA20: $4.44 · SMA50: $5.50

6-Pillar Scorecard Institutional Category Breakdown (BOLD 2 – 4 DERM)

Columns: Metric · BOLD · DERM
1. Valuation Multiples DERM
Forward P/E N/M 8.3x
Trailing P/E N/M 17.6x
PEG Ratio N/M N/M
EV / Revenue N/M 1.5x
2. Growth & Scale DERM
Revenue Growth (YoY) +0.0% +7.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $70M
Market Cap $56.2M $100.2M
3. Profitability & Quality BOLD
Gross Margin N/A 65.9%
Operating Margin 0.0% -2.9%
Net Profit Margin 0.0% -7.3%
Return on Equity (ROE) -64.6% -17.6%
4. Balance Sheet & Cash Flow DERM
Cash Generation (TTM) -$48M -$8.5M
Cash Flow Margin N/A -12.3%
Net Cash / Leverage $31M Net Debt (0.56x D/E) $3.3M Net Debt (0.79x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BOLD
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 17.9% (4th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat DERM
OpEx & R&D Intensity N/A 68.8% of Rev ($48M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BOLD (4) vs DERM (6)
Institutional Metric BOLD DERM Criterion Row Edge
Market Capitalization
Scale
$56.2M $100.2M Larger Scale DERM
Trailing P/E Ratio
Valuation
N/M 17.6x Lower Multiple DERM
Forward P/E Ratio
Valuation
N/M 8.3x Lower Multiple DERM
Revenue Growth (YoY)
Growth
+0.0% +7.6% Higher Growth DERM
Operating Margin (TTM)
Profitability
0.0% -2.9% Higher Margin BOLD
Net Profit Margin
Profitability
0.0% -7.3% Higher Margin BOLD
Return on Equity (ROE)
Capital Efficiency
-64.6% -17.6% Higher ROE DERM
52-Week Range Position
Momentum
62% ($1–$3) 1% ($3–$10) Stronger Trend BOLD
Beta / 30D Volatility
Risk Regime
-0.08β · 28% Vol 2.08β · 77% Vol Lower Realized Risk BOLD
Unified Institutional Score
Composite Signal
36.8 / 100 (SELL) 40.9 / 100 (SELL) Higher Composite DERM
Trailing 12M Revenue (USD)
Operating Scale
N/A $70M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 65.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 1.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$48M ($31M Net Debt (0.56x D/E)) -$8.5M ($3.3M Net Debt (0.79x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BOLD +30.25 pp
BOLD: -4.92% · DERM: -35.17%
3M Horizon BOLD +36.66 pp
BOLD: -21.62% · DERM: -58.28%
6M Horizon BOLD +105.74 pp
BOLD: +61.11% · DERM: -44.63%
1Y Horizon BOLD +158.6 pp
BOLD: +101.74% · DERM: -56.86%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BOLD vs DERM. Trailing 12-month operating profitability (BOLD 0.0% vs DERM -2.9%) and valuation multiples (BOLD N/M vs DERM 8.3x Forward P/E) are benchmarked directly in Pillar 4 below.

BOLD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-64.6% · N/M
DERM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$70M
Gross Margin65.9%
Op. Margin-2.9%
ROE / Fwd P/E-17.6% · 8.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BOLD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BOLD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DERM BREAKDOWN
105d in phase · OBV DISTRIBUTION
Current IV 17.9%
IV Percentile 4th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact DERM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BOLD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $56.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DERM Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $100.2M market capitalization and -2.9% operating margin.
OpEx & R&D Reinvestment 68.8% of Rev ($48M)
90D Engineering Disclosures 0 Published

Investor FAQ BOLD vs DERM Key Questions & Quantitative Answers

As of Nov 20, 2026, Boundless Bio, Inc. (BOLD) captures the overall head-to-head institutional edge over Journey Medical Corporation (DERM) on higher Unified Composite conviction (36.8/100 SELL vs. 40.9/100 SELL) after splitting the core matrix 4–6 (led by Profitability & Quality, Options & Positioning), while DERM wins 4–2 across the 6-pillar growth and valuation breakdown. BOLD trades at $2.32 (N/M Forward P/E, 0.0% operating margin) versus DERM at $3.30 (8.3x Forward P/E, -2.9% operating margin). Composite vs. Pillar Nuance: While DERM currently prints a higher short-term Unified Composite Score (40.9/100 SELL vs. BOLD 36.8/100 SELL), BOLD captures the overall institutional head-to-head verdict (4–6 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -2.9% operating margin) and revenue trajectory (+0.0% vs. +7.6% YoY). Defensive Composite Rating Caution: Although BOLD compares more favorably head-to-head, both BOLD (36.8/100 SELL) and DERM (40.9/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: BOLD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0); meanwhile DERM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DERM leads the Growth & Scale pillar: BOLD posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with DERM at +7.6% YoY revenue growth and +0.0% YoY earnings growth on $70M TTM revenue (65.9% gross margin, -2.9% operating margin). On trailing 12-month operating scale, BOLD generates N/A in USD-normalized revenue versus $70M for DERM. In operating R&D and SG&A reinvestment, BOLD deploys N/A (0 90-day corporate R&D disclosures) versus 68.8% of Rev ($48M) (0 disclosures) for DERM.

DERM screens cheaper on headline valuation multiples. BOLD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas DERM trades at 8.3x Forward P/E, 17.6x Trailing P/E, N/M PEG, and 1.5x EV/Revenue (-12.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BOLD (-64.6% ROE) versus DERM (-17.6% ROE) capital efficiency.

In options market volatility and institutional positioning, BOLD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.08β · 28% Vol realized risk). By comparison, DERM carries 17.9% implied volatility (4th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.08β · 77% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.